30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: Wright Medical

$72.3MM, +19% (U.S. $49.3MM, +16%; ex-U.S. $23.0MM, +26%)

  • Foot/Ankle $46.8MM, +25% (Total Ankle +29%; U.S. $33.9MM, +26%; ex-U.S. $12.9MM, +22%)
  • Upper Extremity $7.4MM, +21% (U.S. $3.7MM, -16%; ex-U.S. $3.6MM, +125%)
  • Biologics $16.1MM, +7% (U.S. $11.0MM, +7%; ex-U.S. $5.0MM, +9%)
  • Other $1.9MM, -12% (U.S. $0.6MM, -26%; ex-U.S. $1.3MM, -2%)


  • Completed integration of Solana Surgical and OrthoPro
  • Added 50 direct sales reps YTD (25 quota-carrying); overall, ~200 reps total (~140 quota-carrying)
  • Average U.S. foot/ankle rep productivity at >$880,000 per direct quota-carrying rep
  • Commenced full U.S. launch of INFINITY Total Ankle Replacement, limited launch in select ex-U.S. countries
  • Talar component of INFINITY is interchangeable with the INBONE II system, which can serve as a revision option
  • Independent survey results indicate total ankle surgeons rank Wright as highest among ankle replacement competitors; results also indicate that #1 barrier to increased adoption is lack of clear revision options
  • New ENVISION revision ankle will proceed to physician testing by year-end
  • Predicting good acceleration of INFINITY cases in 2H14, both from current users and those using competitor products
  • Augment bone graft update: expects FDA’s Office of Device Evaluation to issue approvability determination no later than 10/26/14